medigraphic.com
Anales de Otorrinolaringología Mexicana

2013, Number 4

Next >>

Otorrinolaringología 2013; 58 (4)

Assessment of Quality of Life in Graves’ Ophthalmopathy Patients Subject to Endoscopic Transnasal Orbital Decompression

Reyes GE, Vargas AAM

Language: Spanish
References: 24
Page: 183-190
PDF size: 408.07 Kb.


ABSTRACT

Objective To elucidate if patients underwent a transnasal endoscopic orbital decompression perceive improvement in the quality of life after endoscopic surgery.
Material and method An observational study was made with a case series of 20 patients with a diagnosis of Graves’ ophthalmopathy who underwent a transnasal endoscopic orbital decompression. All of them respond a disease specific quality of life questionnaire for patients with Graves’ ophthalmopathy (the GO-QOL ) about how they felt before and after surgery. The results were compared with the McNemar test (p› 0.05).
Results Before surgery, all patients reported negative changes in appearance. After surgery 45% thought that the ocular changes were still evident, in 50% decreased and 5% reported total improvement. 50% of patients became interested in aesthetics, mostly women and professionals. Those with bilateral surgery showed a greater rate of improvement in visual function and aesthetics. Statistical significance was found for the ability to drive, home activities, reading and watching television, and the frequency with which they took pictures and the need to hide the eye changes because of the disease.
Conclusions Patients operated on endoscopic transnasal orbital decompression improve their quality of life especially if surgery is bilateral. The questionnaire for assessing quality of life in patients with Graves’ ophthalmopathy is a useful tool in assessing the impact of this procedure in the daily life of these patients.


REFERENCES

  1. DeLellis RA. El sistema endócrino. En: Robbins SL, Cotran RS, editores. Patología estructural y funcional 5ª ed. España: Mc Graw-Hill Interamericana, 1995;1242- 1244.

  2. Wartofsky L. Enfermedades del tiroides. En: Harrison TR, Wilson JD. Principios de medicina interna. 14ª ed. España: Mc Graw-Hill Interamericana, 1998;2299-2304

  3. Burch HB, Wartofsky L. Grave’s opthalmophaty: Current concepts regarding pathogenesis and management. Endocr Rev 1993;14:747-793.

  4. Gerding MN, Terwee CB, Dekker FW, Koornneef L, et al. Quality of life in patients with Grave’s ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid 1997;7:885-889.

  5. Marcocci C, Bartalena L, Bogazzi F, Watt T, et al. Studies on the occurrence of ophthalmopathy in Grave’s disease. Acta Endocrinol (Copenh) 1989;120:473-478.

  6. Bahn RS, Heufelder AE. Pathogenesis of Grave’s ophthalmopathy. N Engl J Med 1993;329:1468-1475.

  7. Otto EA, Ochs K, Hansen C, Wall JR, et al. Orbital tissue-derived T lymphocytes from patients with Grave’s ophthalmopathy recognizes autologous orbital antigens. Acta Endocrinol 1996;81:3045-3050.

  8. Sorisky A, Pardasani D, Gagnon A, Smith TJ. Evidence of adipocyte differentiations in human orbital fibroblast in primary culture. J Clin Endocrinol Metab 1996;81:3428-3431.

  9. Bahn RS. A possible role for the thyrotropin receptor in thyroid-associated ophtalmopathy. Orbit 1996;15:119-128.

  10. Burch HB, Wartofsky L. Grave’s opthalmophaty: Current concepts regarding pathogenesis and management. Endocr Rev 1993;14:747-793.

  11. Bartley GB, Fatourechi V, Kadrmas EF. Clinical features of Grave’s ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996;121:284-290.

  12. Gorman CA. Pathogenesis of Grave’s ophthalmopathy. Thyroid 1994;4:379-383.

  13. Bartalena L, Pinchera A, Marcocci C. Management of Grave’s ophthalmopathy: reality and perspectives. Endocrine Reviews 2000;21:168-199.

  14. Farid M, Roch-Levecq AC, Levi L, Brody BL, et al. Psychological disturbance in Graves Ophthalmopathy. Arch Ophtalmol 2005;123:491-496.

  15. Vargas-Aguayo, AM. Técnicas quirúrgicas endoscópicas avanzadas. En: Fundamentos de la cirugía endoscópica de la nariz y senos paranasales. 1ª ed. México: Manual Moderno, 2002;31-34.

  16. Salive ME, Guralnik J, Glynn RJ. Association of visual impairment with mobility and physical function. J Am Geriatr Soc 1994;42:287-292.

  17. Scott IU, Schein OD, West S. Functional status and quality of life measurement among ophthalmic patients. Arc Ophthalmol 1994;112:329-335.

  18. Bartley GB, Fatourechi V, Kadrmas EF. Long-term follow-up of Grave’s ophthalmopathy in an indicent cohort. Ophthalmology 1996;103:958-962.

  19. Kahaly GJ, Hardt J, Petrak F. Psychological factors in subjects with thyroid associated ophthalmopathy. Thyroid 2002;12:237-239.

  20. Fahrenfort JB, Wilterdink AML, van der Veen EA. Long-term residual complains and psychosocial sequelae after remission of hyperthyroidism. Psychoneuroendocrinology 2000;25:201-211.

  21. Harsch I, Paschke R, Usadel KH. The possible etiological role of psychological disturbances in Grave’s disease. Acta Med Austriaca 1992;19(S1):62-65.

  22. Covarrubias-Alamilla C, Vargas-Aguayo A. Descompresión orbitaria transnasal vía endoscópica: experiencia de 10 años. México: UNAM, 2006.

  23. Fraguar M. Definición de la calidad de vida: taxonomia. J Advanced Nursing 1995;22:502-508.

  24. Terwee CB, Gerding MN, Dekker FW, Prummer MF, et al. Development of a disease specific quality of life questionnaire for patients with Grave’s ophthalmopathy: the GO-QOL. Br J Ophthalmol 1998; 82:773-779.




2020     |     www.medigraphic.com